JP2024505195A5 - - Google Patents

Info

Publication number
JP2024505195A5
JP2024505195A5 JP2023544526A JP2023544526A JP2024505195A5 JP 2024505195 A5 JP2024505195 A5 JP 2024505195A5 JP 2023544526 A JP2023544526 A JP 2023544526A JP 2023544526 A JP2023544526 A JP 2023544526A JP 2024505195 A5 JP2024505195 A5 JP 2024505195A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/013666 external-priority patent/WO2022159875A1/en
Publication of JP2024505195A publication Critical patent/JP2024505195A/ja
Publication of JP2024505195A5 publication Critical patent/JP2024505195A5/ja
Pending legal-status Critical Current

Links

JP2023544526A 2021-01-25 2022-01-25 抗pdgf-b抗体及び肺動脈高血圧症(pah)を治療するための使用方法 Pending JP2024505195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141030P 2021-01-25 2021-01-25
US63/141,030 2021-01-25
PCT/US2022/013666 WO2022159875A1 (en) 2021-01-25 2022-01-25 Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)

Publications (2)

Publication Number Publication Date
JP2024505195A JP2024505195A (ja) 2024-02-05
JP2024505195A5 true JP2024505195A5 (https=) 2025-01-30

Family

ID=80446637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544526A Pending JP2024505195A (ja) 2021-01-25 2022-01-25 抗pdgf-b抗体及び肺動脈高血圧症(pah)を治療するための使用方法

Country Status (13)

Country Link
US (2) US12030935B2 (https=)
EP (1) EP4281475A1 (https=)
JP (1) JP2024505195A (https=)
KR (1) KR20230135627A (https=)
CN (1) CN116964088A (https=)
AU (1) AU2022210475A1 (https=)
BR (1) BR112023014337A8 (https=)
CA (1) CA3205846A1 (https=)
CL (1) CL2023002148A1 (https=)
CO (1) CO2023010900A2 (https=)
IL (1) IL304505A (https=)
MX (1) MX2023008691A (https=)
WO (1) WO2022159875A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120028552B (zh) * 2025-02-28 2025-08-19 上海交通大学医学院附属上海儿童医学中心 血小板衍生生长因子pdgf-d在评估右心衰竭中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2436376B1 (en) 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2890483A1 (en) * 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
RU2017120361A (ru) * 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Антитела к pdgf-b и способы их применения

Similar Documents

Publication Publication Date Title
JP2025111463A5 (https=)
CN111744007B (zh) 一种抗tigit抗体药物组合物及其用途
WO2017219995A1 (zh) Lag-3抗体、其抗原结合片段及其医药用途
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
CN112969719A (zh) 双功能融合蛋白及其医药用途
JP6421371B2 (ja) トランスポーターに対する抗体およびその用途
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2010501164A5 (https=)
EP3714901A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
KR20160062167A (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2020515277A5 (https=)
RU2019134462A (ru) Антитела, связывающиеся с steap-1
JP2024024114A5 (https=)
JP2024518844A5 (https=)
JP7377185B2 (ja) 抗ヒトtlr7抗体
JP2024503784A5 (https=)
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
JP2019528046A5 (https=)
CN120603852A (zh) 一种fap/cd40结合分子的药物组合物及其医药用途
TW202402325A (zh) Pvrig/tigit雙特異性抗體藥物組合物及其用途
JP2024505195A5 (https=)
JP2024540435A5 (https=)
JP2021533806A5 (https=)
US20230416352A1 (en) Pharmaceutical composition comprising anti-connective tissue growth factor antibody